BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 22961784)

  • 1. No evidence of increased asparagine levels in the bone marrow of patients with acute lymphoblastic leukemia during asparaginase therapy.
    Tong WH; Pieters R; Hop WC; Lanvers-Kaminsky C; Boos J; van der Sluis IM
    Pediatr Blood Cancer; 2013 Feb; 60(2):258-61. PubMed ID: 22961784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asparagine and aspartic acid concentrations in bone marrow versus peripheral blood during Berlin-Frankfurt-Münster-based induction therapy for childhood acute lymphoblastic leukemia.
    Steiner M; Hochreiter D; Kasper DC; Kornmüller R; Pichler H; Haas OA; Pötschger U; Hutter C; Dworzak MN; Mann G; Attarbaschi A
    Leuk Lymphoma; 2012 Sep; 53(9):1682-7. PubMed ID: 22356135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asparagine levels in the bone marrow of patients with acute lymphoblastic leukemia during asparaginase therapy.
    Chiu M; Franchi-Gazzola R; Bussolati O; D'Amico G; Dell'Acqua F; Rizzari C
    Pediatr Blood Cancer; 2013 Nov; 60(11):1915. PubMed ID: 23900737
    [No Abstract]   [Full Text] [Related]  

  • 4. Asparagine levels in the bone marrow of patients with acute lymphoblastic leukemia during asparaginase therapy.
    Tong WH; Pieters R; Hop WC; van der Sluis IM
    Pediatr Blood Cancer; 2013 Nov; 60(11):1914. PubMed ID: 23813969
    [No Abstract]   [Full Text] [Related]  

  • 5. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase.
    Iwamoto S; Mihara K; Downing JR; Pui CH; Campana D
    J Clin Invest; 2007 Apr; 117(4):1049-57. PubMed ID: 17380207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia.
    Henriksen LT; Nersting J; Raja RA; Frandsen TL; Rosthøj S; Schrøder H; Albertsen BK;
    Br J Haematol; 2014 Jul; 166(2):213-20. PubMed ID: 24702187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IGFBP7 participates in the reciprocal interaction between acute lymphoblastic leukemia and BM stromal cells and in leukemia resistance to asparaginase.
    Laranjeira AB; de Vasconcellos JF; Sodek L; Spago MC; Fornazim MC; Tone LG; Brandalise SR; Nowill AE; Yunes JA
    Leukemia; 2012 May; 26(5):1001-11. PubMed ID: 22005787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
    Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
    Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941).
    Jarrar M; Gaynon PS; Periclou AP; Fu C; Harris RE; Stram D; Altman A; Bostrom B; Breneman J; Steele D; Trigg M; Zipf T; Avramis VI
    Pediatr Blood Cancer; 2006 Aug; 47(2):141-6. PubMed ID: 16425271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow].
    Schrappe M; Reiter A; Sauter S; Ludwig WD; Wörmann B; Harbott J; Bender-Götze C; Dörffel W; Dopfer R; Frey E
    Klin Padiatr; 1994; 206(4):208-21. PubMed ID: 7526027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia.
    Rizzari C; Citterio M; Zucchetti M; Conter V; Chiesa R; Colombini A; Malguzzi S; Silvestri D; D'Incalci M
    Haematologica; 2006 Jan; 91(1):24-31. PubMed ID: 16434367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations.
    Boos J; Werber G; Ahlke E; Schulze-Westhoff P; Nowak-Göttl U; Würthwein G; Verspohl EJ; Ritter J; Jürgens H
    Eur J Cancer; 1996 Aug; 32A(9):1544-50. PubMed ID: 8911116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct fluctuations of ammonia levels during asparaginase therapy for childhood acute leukemia.
    Steiner M; Attarbaschi A; Kastner U; Dworzak M; Haas OA; Gadner H; Mann G
    Pediatr Blood Cancer; 2007 Oct; 49(5):640-2. PubMed ID: 16941647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An isocratic fluorescence HPLC assay for the monitoring of l-asparaginase activity and l-asparagine depletion in children receiving E. colil-asparaginase for the treatment of acute lymphoblastic leukaemia.
    Nath CE; Dallapozza L; Eslick AE; Misra A; Carr D; Earl JW
    Biomed Chromatogr; 2009 Feb; 23(2):152-9. PubMed ID: 18823071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
    van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE
    Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia.
    Woo MH; Hak LJ; Storm MC; Gajjar AJ; Sandlund JT; Harrison PL; Wang B; Pui CH; Relling MV
    J Clin Oncol; 1999 May; 17(5):1568-73. PubMed ID: 10334545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
    Winter SS; Holdsworth MT; Devidas M; Raisch DW; Chauvenet A; Ravindranath Y; Ducore JM; Amylon MD
    Pediatr Blood Cancer; 2006 Feb; 46(2):179-86. PubMed ID: 16007607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia.
    Wenner KA; Vieira Pinheiro JP; Escherich G; Wessalowski R; Jorch N; Wolff J; Stehn M; Kohlschütter A; Boos J; Janka-Schaub GE
    Klin Padiatr; 2005; 217(6):321-6. PubMed ID: 16307417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.
    Den Boer ML; Harms DO; Pieters R; Kazemier KM; Gobel U; Körholz D; Graubner U; Haas RJ; Jorch N; Spaar HJ; Kaspers GJ; Kamps WA; Van der Does-Van den Berg A; Van Wering ER; Veerman AJ; Janka-Schaub GE
    J Clin Oncol; 2003 Sep; 21(17):3262-8. PubMed ID: 12947061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.